MaxCyte Inc — Cash Flow (NASDAQ:MXCT) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -10.68 M-14.78 M21.69 M27.61 M 39.54 M Cash from investing activities -195.01 M-24.82 M54.98 M6.93 M 14.59 M Cash from financing activities 234.72 M2.89 M2.14 M2.06 M 963 K Free cash flow -14.51 M-33.26 M17.99 M25.96 M 37.86 M

Nouvelles

Cellares appoints Ali Soleymannezhad as chief commercial officer

MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript

MaxCyte CFO Douglas Swirsky to step down in first half of 2026

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates

Masoud Maher buys Maxcyte (MXCT) shares worth $102,915

Maxcyte CFO Swirsky buys $64.5k in shares

Brooke William buys Maxcyte (MXCT) shares worth $64,500

Douglas buys $111k in Maxcyte shares

Erck Stanley C, Maxcyte director, buys $137k in MXCT stock

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - C3.ai (NYSE:AI), Aspen Aerogels (NYSE:ASPN)

MaxCyte stock rating downgraded to Neutral by BTIG on funding concerns